Given that C. jejuni induced pathologies include the activation of the mammalian target of rapamycin (mTOR) and were ameliorated by rapamycin treatment in IL-10−/− mice [48], it is noteworthy that urolithin-A was reported to downregulate mTOR dependent pathways in cancer cells [49]. This evidence concerns the gene MTOR and cancer.